Participating in a vaccine trial for COVID-19 in Senegal: trust and information

12Citations
Citations of this article
56Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

This research aims to understand the level and determinants of people’s willingness to participate in a vaccine trial for COVID-19 in Senegal. We conducted a telephone survey among a marginal quota sample of 607 people over 18 years of age. Only 44.3% of the participants wanted to participate in a vaccine trial for COVID-19, with females intending to participate more than males (AOR = 1.82, 95% CI [1.22–2.72]). Participants who intended to be vaccinated against COVID-19 (AOR = 6.48, 95% CI [4.12–10.4]) and who thought that being infected with the coronavirus would have a significant impact on their health (AOR = 2.34, 95% CI [1.57, 3.51]) were more likely to agree to take part in the COVID-19 vaccine trial. Confidence in the vaccine, health personnel, and the government in the fight against the pandemic are key factors in participants’ willingness to participate in a vaccine trial in Senegal.

Cite

CITATION STYLE

APA

Ridde, V., Ba, M. F., Gaye, I., Diallo, A. I., Bonnet, E., & Faye, A. (2021). Participating in a vaccine trial for COVID-19 in Senegal: trust and information. Human Vaccines and Immunotherapeutics, 17(11), 3907–3912. https://doi.org/10.1080/21645515.2021.1951097

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free